Target intelligence / Profile preview

SARS-CoV-2 viral RNA

Molecular classification
Other (single-stranded, positive-sense RNA virus genome)
01

Overview

SARS-CoV-2 viral RNA is a single-stranded, positive-sense RNA molecule approximately 29.9 kb in length that serves as both the genomic material and the messenger RNA for the coronavirus SARS-CoV-2, which causes COVID-19[1][5][7]. The genome contains a 5′ cap and a 3′ poly(A) tail and encodes 13 or more open reading frames for structural, nonstructural, and accessory proteins[5]. The RNA features complex secondary and tertiary structures, including stem-loops and long-range interactions, which regulate viral replication, transcription, translation, and evasion of the host immune response[1][3][6][7]. The genome acts as the template for synthesis of both new viral genomes and subgenomic RNAs during infection, making it a key molecular hub and a validated antiviral drug target. Drugs such as remdesivir and molnupiravir specifically act on viral RNA synthesis by inhibiting the RNA-dependent RNA polymerase or introducing mutations during replication[4]. Quantification of viral RNA in patient samples is widely used for diagnosis and management of COVID-19. The adaptability of the RNA genome poses challenges for therapy due to the risk of resistance and mutation[1][5].

Other names
SARS-CoV-2 RNA genomeSevere acute respiratory syndrome coronavirus 2 RNASARS-CoV-2 genomic RNASARS-CoV-2 gRNA
02

Mechanism of action

Inhibitors of viral RNA-dependent RNA polymerase (e.g., remdesivir: nucleotide analog acts as a chain terminator); Induction of lethal mutagenesis (e.g., molnupiravir); Direct cleavage/degradation of viral RNA (e.g., siRNA, antisense oligonucleotides)

03

Biological functions

Viral genome encodingTemplate for viral replicationTemplate for viral transcriptionRegulation of viral protein translationRNA packagingEvasion of host immunity
04

Disease associations

Infection (COVID-19)
05

Safety considerations

High error rate of viral RNA replication enables rapid emergence of resistance mutations.Off-target effects for RNA-targeting drugs (siRNA, antisense).Host immune responses to RNA-based therapeutic interventions.
06

Interacting drugs

Remdesivir

4 more in the full profile.

07

Biomarkers

Viral RNA titer in biological samples (e.g., RT-PCR testing for SARS-CoV-2 RNA)Quantitative viral load (used to monitor infection and response to treatment)

Beyond the preview

Go deeper on SARS-CoV-2 viral RNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SARS-CoV-2 viral RNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call